^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Excerpt:
...- Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers

Excerpt:
...we conducted a multicohort “basket” study of the BRAF inhibitor vemurafenib in non-melanoma BRAFV600 mutation–positive solid tumors. In total, 172 patients with 26 unique cancer types were treated, achieving an overall response rate of 33% and median duration of response of 13 months. Responses were observed in 13 unique cancer types, including historically treatment-refractory tumor types such as cholangiocarcinoma, sarcoma, glioma, neuroendocrine carcinoma, and salivary gland carcinomas. 
DOI:
10.1158/2159-8290.CD-19-1265
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Excerpt:
The primary objective of the study was to evaluate the efficacy of vemurafenib in patients with BRAF V600 mutation–positive cancers...Responses were also observed in patients with the following tumor types: anaplastic thyroid cancer (two patients), cholangiocarcinoma (one patient)...
DOI:
https://dx.doi.org/10.1056%2FNEJMoa1502309
Trial ID: